An audit of long-term octreotide therapy for acromegaly

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 1, 1997, Pages 12-18

  Cheung, N W ^a   Taylor, L ^a   Boyages, S C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Acromegaly; Octreotide

Indexed keywords

OCTREOTIDE; SOMATOMEDIN C;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INJECTION PAIN; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY; VOMITING;

EID: 0030939418     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00907.x     Document Type: Article

References (27)

1. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980; 12: 71-9.
2. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. QJMed 1970; 153: 1-16.
3. Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. Acta Med Scand 1988; 223: 327-35.
4. Nabarro JDN. Acromegaly. Clin Endocrinol 1987; 26: 481-512.
5. Ezzat S, Melmed S. Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72:245-9.
6. Harris AG. Acromegaly. Basle: Sandoz Pharma, 1991; 80-9.
7. Baxter RC, Brown AS, Turtle JR. Radioimmunoassay for somatomedin-C: comparison with radioreceptor assay in patients with growth-hormone disorders, hypothyroidism, and renal failure. Clin Chem 1982; 28: 488-95.
8. Zeger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
9. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991; 151: 1573-8.
10. Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly. Ann Intern Med 1992; 117: 711-8.
11. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402.
12. Lamberts SWJ, Uitterrlinden P, del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients over two years. J Clin Endocrinol Metab 1987; 65: 703-10.
13. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Ann Intern Med 1990; 112: 173-81.
14. Shi YF, Harris AG, Zhu XF, Deng JY. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients. Clin Endocrinol 1990; 32: 695-705.
15. James RA, Chatterjee S, White MC, Hall K, Moller N, Kendall-Taylor P. Continuous infusion of octreotide in acromegaly. Lancet 1989; ii: 1083-7.
16. Montini M, Gianola D, Pagani MD, Pedroncelli A, Caldara R, Gherardi F. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol 1994; 40: 401-6.
17. Acromegaly Therapy Consensus Development Panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97: 468-73.
18. Fahlbusch R, Honneger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin N Am 1992; 21: 669-92.
19. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 1993; 78: 205-15.
20. Losa M, Oeckler R, Schopohl J, Muller A, Alba-Lopez J, von Werder K. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly. J Neurosurg 1989; 70: 561-7.
21. Barkan AL. Acromegaly: diagnosis and therapy. Endocrinol Metab Clin N Am 1989; 18: 277-309.
22. Eastman AC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979; 48: 931-40.
23. Al-Mefty O, Kersh JE, Routh A, Smith RR. The longterm side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 1990; 73: 502-12.
24. Grattan-Smith PJ, Morris JG, Langlands AO. Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours. J Neurol Neurosurg Psych 1992; 55: 949-55.
25. Ron E, Modan B, Boice JD et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988; 319: 1033-9.
26. Brada M, Ford D, Ashley S et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992; 304: 1343-6.
27. Jaffe A, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin N Am 1992; 21:713-35.